The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical utility of upfront circulating tumor DNA (ctDNA) genotyping to guide first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC): A GOZILA substudy.
 
Yu Aoki
Honoraria - Guardant Health
 
Yoshiaki Nakamura
Honoraria - Chugai Pharma; Guardant Health AMEA; Merck
Research Funding - Chugai Pharma (Inst); Genomedia (Inst); Guardant Health (Inst); Guardant Health (Inst); Roche (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
 
Yoshito Komatsu
No Relationships to Disclose
 
Hiroya Taniguchi
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.; Merck Serono; Mitsubishi Tanabe Pharma; MSD K.K; Nippon Kayaku; Novartis; Ono Yakuhin; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Array BioPharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); MSD Oncology (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Sysmex (Inst); Takeda (Inst)
 
Yu Sunakawa
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Guardant Health; Incyte; Lilly Japan; Merck; MSD K.K; Ono Pharmaceutical; Sysmex; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo; Merck; MSD K.K
Research Funding - Chugai Pharma; Lilly Japan; Otsuka; Taiho Pharmaceutical; Takeda
 
Manabu Shiozawa
Speakers' Bureau - Johnson & Johnson; Kaken Pharmaceutical; Lilly Japan; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Chiyoe Kitagawa
Speakers' Bureau - Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Ono Yakuhin
Research Funding - Abbvie; Daiichi Sankyo/Astra Zeneca; MSD; Ono Yakuhin; Sanofi
 
Takashi Ohta
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; EA Pharma; Eisai; Merck KGaA; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Honsha
Research Funding - Takeda
 
Nobuhisa Matsuhashi
No Relationships to Disclose
 
Kentaro Yamazaki
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Taiho Pharmaceutical (Inst)
 
Shogen Boku
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; MSD; Taiho Pharmaceutical
Research Funding - Daiichi Sankyo Co. Ltd. (Inst)
 
Naoki Takahashi
Honoraria - Bristol-Myers Squibb Japan; Ono Pharmaceutical; Taiho Pharmaceutical
 
Taito Esaki
Honoraria - Bristol-Myers Squibb Japan (Inst); Chugai Pharma; Daiichi Sankyo; Lilly; Taiho Pharmaceutical
Research Funding - Amgen (Inst); Amgen Astellas BioPharma (Inst); Asahi Kasei (Inst); Astellas Pharma (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); DainipponSumitomo (Inst); DainipponSumitomo (Inst); Eisai (Inst); IQVIA (Inst); Lilly (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Parexel (Inst); Pfizer (Inst); Quintiles (Inst); Syneos Health (Inst)
 
Hisato Kawakami
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo; Lilly Japan; Merck Serono; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo Co. Ltd.,; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kobayashi Pharmaceutical (Inst)
 
Yoshinori Kagawa
Consulting or Advisory Role - Lilly; Merck; Taiho Pharmaceutical
Speakers' Bureau - Bayer; Chugai Pharma; Lilly; Merck; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Research Funding - Ono Pharmaceutical
 
Tomohiro Nishina
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Lilly Japan (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Kensei Yamaguchi
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Hideaki Bando
Honoraria - Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
 
Takayuki Yoshino
Honoraria - Bayer Yakuhin; Chugai Pharma; Merck; MSD K.K.; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Sumitomo Corp.
Research Funding - Amgen (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Eisai (Inst); FALCO biosystems Ltd. (Inst); Genomedia (Inst); Molecular Health (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst)